Jeito
  • About
  • The team
  • Our portfolio
  • ESG & Impact
  • Newsroom
  • Contact
  • English
    • Français
    • English
Select Page

Jeito Capital leads EUR 132 million oversubscribed Series B financing in Azafaros to advance Phase 3 clinical programs of innovative therapies in rare inherited neuro-metabolic disorders

by Certifié Conforme | 13 May Tue | English

Proceeds will support two Phase 3 pivotal programs with nizubaglustat, lead asset in Niemann-Pick disease Type C disease and GM1/GM2 gangliosidoses, three forms of rare lysosomal storage disorders, as well as expanding Azafaros pipeline to other indications The...
Jeito Capital Strengthens Leadership for Next Chapter of Growth:Mehdi Ainouche Promoted to Partner, Julien Elric to Senior Principal

Jeito Capital Strengthens Leadership for Next Chapter of Growth:Mehdi Ainouche Promoted to Partner, Julien Elric to Senior Principal

by Certifié Conforme | 12 May Mon | English

Paris, May 12 2024 – Jeito Capital (“Jeito”), a global leading independent Private Equity fund dedicated to biopharma, is pleased to announce the promotion of Mehdi Ainouche to Partner and Julien Elric to Senior Principal. These promotions represent the next...

Recent Posts

  • Jeito Capital promotes Ksenija Pavletic to General Partner
  • Jeito Capital announces significant participation in oversubscribed $213M Series D financing for Odyssey Therapeutics to advance clinical pipeline addressing autoimmune diseases with high unmet needs
  • Jeito Capital appoints Pascal Touchon as Operating Partner
  • Jeito Capital Leads a USD 65 million Financing in ReproNovo to Develop Transformational Treatments in Reproductive Medicine and Women’s Health
  • Jeito Capital leads EUR 132 million oversubscribed Series B financing in Azafaros to advance Phase 3 clinical programs of innovative therapies in rare inherited neuro-metabolic disorders

Recent Comments

    Mentions et autres liens
    We use cookies to provide you with the best possible website experience by
    offering you tailored content and for statistical purposes. You can modify your
    choices at any time. For more information, please consult our cookie policy.
    Cookie settingsAccept allReject all
    Manage consent

    Privacy Overview

    This website uses cookies to improve your experience while browsing the site. Among these, cookies that are categorized as necessary are stored on your browser as they are essential for the basic functionality of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will only be stored in your browser with your consent. You also have the option to decline these cookies. However, disabling some of these cookies may affect your browsing experience.
    Necessary
    Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
    SAVE & ACCEPT